Faced with osteoarthritis, a chronic joint disease and a major cause of disability, medicine still lacks drugs capable of truly slowing the progression of the disease. In a study published on August 6, 2026 in the journal ACS Omegaresearchers combined human genetics and artificial intelligence to find a first candidate who does not just relieve pain, but targets the deeper mechanisms of the disease.
This compound, called M04was developed by a team from the University of Utah Health led by Michael J. Jurynec, specialist in orthopedic surgery. “Our focus really comes down to treating patients,” says Michael J. Jurynec. “Currently, the only treatments available for osteoarthritis are the installation of a joint prosthesis or the taking of painkillers. If we can find a way to slow the progression of the disease and give patients an additional 10 to 20 years of pain-free life, that will be a major breakthrough.“Where current treatments are mainly symptomatic, M04 is thought to be a future “disease-modifying” drug.
How AI Helped Target WNK2 to Treat Osteoarthritis
The researchers didn’t start from scratch: studies of Utah families followed in the Utah Population Database had already shown that rare variants of the gene WNK2
cause highly hereditary forms of osteoarthritis. When WNK2 is too active in chondrocytes, the cartilage cells, it triggers inflammatory signals that make joints more vulnerable and accelerate tissue breakdown.
From this target validated by human genetics, the team used a structural biology AI tool to predict the three-dimensional shape of the WNK2 protein, then simulated the interaction of approximately 500,000 chemical compounds with this structure. This virtual screen provided just over 50 molecules capable of binding to WNK2; After visual inspection, scientists selected only six for laboratory testing.
What candidate M04 does on human cartilage cells
The six candidates were then evaluated in an osteoarthritis model on human chondrocytes placed in an inflammatory environment reproducing that of a diseased joint. Only one, M04, really changed the game. “We treated cells with this new compound that we discovered, and it inhibited many, many genes associated with osteoarthritis.“, reports Michael J. Jurynec. “Not only did it inhibit these inflammatory factors, but it actually increased the expression of genes that promote the health of these cells“.
Biologically, M04 lowers the activity of many genes linked to inflammation and osteoarthritis, while stimulating genes associated with healthy cartilage, the authors show in
ACS Omega. A future “modifying” treatment will have to rebalance this set of programs rather than blocking a single molecule.
M04 and WNK2: still very early hope for osteoarthritis
For the moment, tests have only been carried out in the laboratory, on cells in culture. The team, in conjunction with the University of Utah Therapeutics Accelerator Hub, must still optimize the molecule, verify its toxicity and effectiveness in animals, before considering any clinical trial in humans.
“This is truly the beginning of the study“, explains Jurynec. “This is not the end. We don’t yet have a drug that will cure osteoarthritis. But it’s very promising.”.